The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

The company's older weight loss drug, liraglutide, is marketed as Victoza for diabetes and Saxenda for weight loss. Because Eli Lilly's tirzepatide did not hit the market as Mounjaro for diabetes ...